← National Vision Holdings, Inc. (EYE) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
National Vision Holdings, Inc. (EYE)
Ophthalmic Goods · market cap $1.3B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
National Vision Holdings (EYE) is a retail optical chain operating in the Ophthalmic Goods sector with a market cap of ~$1.66B and approximately 80M shares outstanding at ~$20.73. Despite the anomalous pipeline data attributing vaccine assets to this ticker, National Vision is a brick-and-mortar optical retail business with $1.99B in 2025 revenue and a net debt position of $178.6M against only $67.9M in cash. The nearest identified catalyst is an August 5, 2026 earnings release.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Inactivated SARS-CoV-2 Vaccine (Vero cell) | Phase 3 | COVID-19 |
| Diphtheria,Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed | Phase 3 | Whooping Cough |
| SARS-CoV-2 Vaccine (Vero Cell), Inactivated | Phase 3 | COVID-19 Pneumonia |
Price & technical context
3-month
-17.9%
6-month
-30.8%
12-month
-43.6%
52-wk range
$15.44–$29.46
vs 50-day MA
-11.7%
vs 200-day MA
-26.7%
Realized vol
52.0%
Max drawdown
-47.6%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EYE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.